Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections

Neonatal Infections: Sepsis Syndromes and Congenital Pathogens

Neonates possess an immature immune system characterized by deficient complement activity, impaired neutrophil chemotaxis, low concentrations of endogenous immunoglobulins (with preterm infants lacking transplacental maternal IgG acquired primarily during the third trimester), and naive cell-mediated immunity. Consequently, systemic bacterial infections and congenital intrauterine pathogens carry high mortality and lifelong neurodevelopmental morbidity.

---

Early-Onset vs. Late-Onset Neonatal Sepsis

Systemic neonatal bacterial infections are categorized according to the timing of clinical presentation, reflecting fundamentally different modes of transmission, microbial etiologies, and clinical courses.

---

Group B Streptococcus (GBS) and Intrapartum Antibiotic Prophylaxis

Streptococcus agalactiae (Group B Streptococcus) is a Gram-positive diplococcus colonizing the gastrointestinal and genitourinary tracts of 15% to 30% of pregnant women. Without intervention, 50% of infants born to colonized mothers become colonized, and 1% to 2% develop invasive early-onset GBS disease (sepsis, pneumonia, or meningitis).

Maternal Screening and Indications for Prophylaxis

GBS prevention follows national policy: the UK does not recommend universal screening; some European programmes use vaginal-rectal cultures at 35–37 weeks, while US ACOG uses 36+0–37+6 weeks. In culture-based/risk-based pathways, intrapartum antibiotic prophylaxis (IAP) is indicated during labour or after membrane rupture for:

1. Positive maternal vaginal-rectal GBS culture during current pregnancy
2. Documented GBS bacteriuria or urinary tract infection at any point during current pregnancy
3. Previous infant delivered with invasive GBS disease
4. Unknown GBS colonization status at onset of labor combined with any intrapartum risk factor:
   • Preterm delivery (<37 weeks gestation)
   • Prolonged rupture of membranes (PROM) ≥18 hours
   • Maternal intrapartum fever ≥38.0°C (100.4°F)

GBS-specific IAP is not required for prelabour caesarean birth with intact membranes, even with a positive culture. Suspected intra-amniotic infection requires appropriate broad-spectrum maternal treatment, rather than GBS prophylaxis alone.

Recommended IAP Regimens

• First-Line: Intravenous Benzylpenicillin (Penicillin G): 5 million units IV loading dose, followed by 2.5 to 3.0 million units IV every 4 hours until delivery; OR Intravenous Ampicillin: 2 g IV loading dose, then 1 g IV every 4 hours until delivery.
• Adequacy for Neonatal Risk Assessment: ≥4 hours of IV penicillin, ampicillin or cefazolin constitutes adequate IAP in categorical neonatal algorithms. Shorter exposure still offers benefit; do not delay necessary obstetric interventions solely to reach 4 hours.
• Penicillin Allergy Regimens:
  • Low risk for anaphylaxis (e.g., maculopapular rash): Intravenous Cefazolin (2 g loading, then 1 g q8h).
  • High risk for anaphylaxis (e.g., bronchospasm, angioedema, urticaria): If GBS isolate is known susceptible, Intravenous Clindamycin (900 mg q8h). If resistant or susceptibility unknown, Intravenous Vancomycin (ACOG: 20 mg/kg q8h, maximum 2 g per dose, with dosing based on weight and renal function).

---

Diagnostic Evaluation of Suspected Neonatal Sepsis

The clinical signs of neonatal sepsis are notoriously subtle, non-specific, and easily confused with transitional adaptation or metabolic instability:

• Thermal Instability: Hypothermia (<36.5°C) is far more common than fever (>37.5°C), particularly in premature infants.
• Respiratory Distress: Tachypnea, grunting, intercostal retractions, increased oxygen requirement, or new-onset unexplained apnea.
• Hemodynamic Instability: Tachycardia, delayed capillary refill time (>3 seconds), weak peripheral pulses, hypotension, cool/mottled extremities.
• Neurological Depression: Lethargy, irritability, hypotonia, weak suck, high-pitched cry, or seizures.
• Gastrointestinal Dysfunction: Feeding intolerance, abdominal distension, vomiting, or bilious gastric aspirates.

Laboratory Workup Protocol

1. Blood Culture: The absolute gold standard. A minimum volume of 1.0 mL of blood must be inoculated into an aerobic blood culture bottle prior to administering antibiotics. Volumes <0.5 mL yield unacceptably high false-negative rates due to low-level bacteremia (1-10 CFU/mL).
2. Complete Blood Count with Differential:
   • Leukopenia (total WBC <5,000/µL) has higher specificity for sepsis than leukocytosis (WBC >25,000-30,000/µL).
   • Immature to Total Neutrophil Ratio (I:T Ratio): Calculated as $\frac{\text{Bands + Metamyelocytes + Myelocytes}}{\text{Total Neutrophils}}$. An I:T ratio >0.20 reflects a pathological left shift indicating bone marrow neutrophil release.
   • Thrombocytopenia (platelet count <100,000/µL): Frequently accompanies severe sepsis and disseminated intravascular coagulation (DIC).
3. Inflammatory Biomarkers (C-Reactive Protein and Procalcitonin):
   • C-Reactive Protein (CRP): Synthesized by hepatocytes in response to IL-6. CRP rises slowly, beginning 10 to 12 hours after infectious insult and peaking at 36 to 48 hours. A normal CRP at symptom onset cannot exclude sepsis. Serial reassuring CRP results can support stopping treatment, but must not determine the decision alone. Interpret them with blood cultures, the initial likelihood of infection and the infant’s clinical course.
   • Procalcitonin (PCT): Rises faster (2-4 hours). However, neonates experience a physiological surge in procalcitonin during the first 48 hours after birth, requiring gestational age- and hour-specific cutoffs.
4. Lumbar Puncture (LP):
   • Perform when safe if neonatal infection is strongly suspected or there are signs of meningitis; do not wait for a positive blood culture. Meningitis may occur with a negative blood culture.
   • Also consider LP after a positive blood culture or poor treatment response if not done initially. Stabilise respiratory/circulatory compromise or uncontrolled seizures first; do not delay urgent antibiotics for an unsafe LP.
5. Urine Culture: Follow the care setting. NICE advises against routine urine culture for EOS or for LOS in neonatal units, but recommends it for suspected LOS outside neonatal units. Obtain an appropriate uncontaminated specimen, usually by catheterisation or suprapubic aspiration in an ill neonate. Urinary infection is uncommon in EOS, so initial investigation focuses on blood cultures and clinical assessment.

---

Empiric Antimicrobial Regimens

Suspected Neonatal Sepsis
           │
           ├─────────────────────────────────────────┐
           ▼                                         ▼
Early-Onset Sepsis (<72h)                 Neonatal-Unit LOS (≥72h)
Vertical Pathogens (GBS, E. coli, Listeria)   Nosocomial / Catheter Pathogens (CoNS, S. aureus, GNR)
           │                                         │
           ▼                                         ▼
  IV AMPICILLIN                             IV FLUCLOXACILLIN (or VANCOMYCIN)
        +                                            +
  IV GENTAMICIN                             IV GENTAMICIN / AMIKACIN
(Synergistic bactericidal GBS kill;         (Add Meropenem / Ceftazidime if
 covers Gram-negative coliforms)            Pseudomonas or resistant GNR suspected)
           │                                         │
           ▼                                         ▼
Reassess EOS at 36–48 hours:               If invasive Candida suspected
Negative culture + low initial suspicion   (VLBW, central line, platelets plummeting):
+ well infant + reassuring CRP trend        ──► Add AMPHOTERICIN B
──► STOP; otherwise reassess ongoing need

Early-Onset Sepsis Empiric Therapy

• IV Ampicillin + IV Gentamicin: Ampicillin provides robust coverage against Streptococcus agalactiae, Listeria monocytogenes, and susceptible enterococci. Gentamicin provides broad coverage against Gram-negative Enterobacteriaceae (E. coli, Klebsiella) and acts synergistically with ampicillin to accelerate bacterial killing of GBS.
• Community-Onset Infection and Ceftriaxone Restrictions: NICE uses a third-generation cephalosporin plus ampicillin/amoxicillin for Listeria coverage in young infants presenting from home. For neonates, NICE permits ceftriaxone only above 40 weeks corrected gestation without IV calcium; otherwise use cefotaxime, while also respecting the contraindications below. Ceftriaxone is contraindicated in premature neonates up to 41 weeks postmenstrual age, neonates with impaired bilirubin binding (including jaundice), and neonates ≤28 days needing or expected to need IV calcium. Bilirubin displacement can increase neurotoxicity risk; calcium-ceftriaxone precipitation can cause fatal organ injury. Follow the national sepsis/meningitis pathway and local resistance data.
• Antibiotic Stewardship: Stop empiric EOS antibiotics at 36–48 hours when cultures are negative, initial suspicion was low, the infant is well and inflammatory-marker trends are reassuring. NICE specifies 36 hours for EOS and consideration at 48 hours for LOS. Strongly suspected culture-negative infection requires continued assessment and treatment; CRP alone cannot decide cessation.

Treatment Durations for Confirmed Infection

• Uncomplicated bacteremia: 7 to 10 days
• Group B Streptococcal meningitis: 14 days
• Gram-negative bacillary meningitis (E. coli): 21 days (or at least 14 days after documentation of CSF sterilization)

---

Congenital TORCH Infections

The TORCH complex encompasses transplacental and perinatal infections caused by Toxoplasmosis, Other (Syphilis, Varicella, Parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes Simplex Virus (HSV). While each pathogen produces distinct clinical hallmarks, they share overlapping features of intrauterine growth restriction (IUGR), hepatosplenomegaly, microcephaly, thrombocytopenia, and jaundice.

Clinical Distinctions Among TORCH Infections

      INTRACRANIAL CALCIFICATIONS PATTERN
   ┌────────────────────────────────────────┐
   │                                        │
   ▼                                        ▼
PERIVENTRICULAR                       DIFFUSE PARENCHYMAL
(Lining the lateral ventricles)       (Scattered across cortex & basal ganglia)
   │                                        │
   ▼                                        ▼
CONGENITAL CMV                         CONGENITAL TOXOPLASMOSIS
(+ Microcephaly, SNHL)                 (+ Hydrocephalus, Chorioretinitis)

Congenital Cytomegalovirus (CMV): Detailed Management

CMV is the leading non-genetic cause of sensorineural hearing loss and neurodevelopmental disability in developed nations. Approximately 85% to 90% of infected neonates are asymptomatic at birth; however, 10% to 15% of these asymptomatic infants will develop progressive sensorineural hearing loss during childhood.

• The 21-Day Diagnostic Window: Test urine or saliva for CMV DNA within the first 21 days of life; a positive saliva result requires confirmatory urine PCR because breast-milk contamination can cause false positives. Testing beyond day 21 cannot distinguish congenital infection from postnatally acquired CMV (e.g., through maternal breast milk or transfusion), which does not carry the same neurodevelopmental risks.
• Pharmacological Treatment: In infants with symptomatic congenital CMV disease involving the central nervous system (microcephaly, abnormal neuroimaging, chorioretinitis, hearing loss) or severe organ involvement, oral valganciclovir (16 mg/kg/dose twice daily) administered for 6 months can modestly improve longer-term hearing and neurodevelopmental outcomes; it does not guarantee hearing preservation. The major dose-limiting adverse effect is neutropenia, requiring regular monitoring of absolute neutrophil counts (ANC).

Neonatal Herpes Simplex Virus (HSV): Clinical Syndromes and Pitfalls

Neonatal HSV infection presents in three clinically distinct forms, typically appearing between the first and third weeks of life:

1. Skin, Eye, and Mouth (SEM) Disease (45%): Presents at 1 to 2 weeks with localized vesicular lesions on an erythematous base, keratoconjunctivitis, and oral ulcers. Without treatment, >70% of SEM cases progress to CNS or disseminated disease.
2. Central Nervous System (CNS) Disease (30%): Presents at 2 to 3 weeks with lethargy, irritability, temperature instability, focal seizures, and CSF pleocytosis (elevated protein and lymphocytic pleocytosis). Critical Exam Fact: Up to 30% to 40% of neonates with CNS HSV disease NEVER develop skin vesicles!
3. Disseminated Disease (25%): Presents at 9 to 11 days with fulminant septic shock, multiorgan failure, disseminated intravascular coagulation (DIC), severe hepatitis with profound coagulopathy, and pneumonitis. Mortality exceeds 30% even with aggressive treatment.